Autopsy report · NCT02980029

TVB 2640 for Resectable Colon Cancer Other Resectable Cancers; a Window Trial.

“Study was terminated by the PRMC for low accrual”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 year before it started.
• Ran for about 6 years 1 month before it stopped.
• 23 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Mark Evers

Sponsor type

University, hospital or other

Conditions

Colon Cancer

Interventions

TVB-2640; Placebo

Participants

23

Sites

1

Countries

United States

Trials that died the same way

• Anti-MART-1 F5 Cells Plus ALVAC MART-1 Vaccine to Treat Advanced Melanoma
  “The study was terminated due to low accrual.” (76% match in meaning)
• Bevacizumab (Avastin) in Unresectable/Recurrent Hemangioblastoma From Von-Hippel-Lindau Disease
  “Study terminated due to low accrual.” (74% match in meaning)
• Goserelin Acetate Study for Ovarian Function in Patients With Primary Breast Cancer
  “Study stopped due to low accrual.” (72% match in meaning)
• Naltrexone Treatment for Prolonged Grief Disorder (PGD)
  “We are terminating the study due to low accrual.” (72% match in meaning)
• Pembrolizumab + Idelalisib for Lung Cancer Study
  “The study was terminated due to poor accrual.” (71% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.